Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7456 to 7470 of 7707 results

  1. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued [GID-TA10072]

    Technology appraisal guidance
    Discontinued

  2. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

    Technology appraisal guidance
    Discontinued

  3. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued [GID-TA10047]

    Technology appraisal guidance
    Discontinued

  4. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued [GID-TA10045]

    Technology appraisal guidance
    Discontinued

  5. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    In development [GID-TA11357] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  7. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued [GID-TAG321]

    Technology appraisal guidance
    Discontinued

  8. Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

    Discontinued [GID-TAG300]

    Technology appraisal guidance
    Discontinued

  9. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued [GID-TAG278]

    Technology appraisal guidance
    Discontinued

  10. Multiple sclerosis - sativex [ID387]

    Discontinued [GID-TAG368]

    Technology appraisal guidance
    Discontinued

  11. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued [GID-TA10242]

    Technology appraisal guidance
    Discontinued

  12. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued [GID-TA11209]

    Technology appraisal guidance
    Discontinued

  13. Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]

    In development [GID-TA11472] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants (IPG270)

    This guidance has been updated and replaced by NICE interventional procedures guidance 795.

    Interventional procedures guidance
    Published
    23 July 2008

  15. EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

    Medtech innovation briefing
    Published
    10 November 2015